CD38 and chronic obstructive pulmonary disease: In clinical practice, it is important to recognize that patients with severe respiratory or cardiac conditions should only receive anti-CD38-based therapies with appropriate monitoring supportive measures, such as bronchodilator prophylaxis in patients with COPD receiving daratumumab.